Rise Therapeutics Completes Enrollment in Four-Week Dose Expansion Cohort for the R-2487 Rheumatoid Arthritis Clinical Trial

ROCKVILLE, MD, June 2, 2026 /PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company advancing novel oral immunotherapies for autoimmune diseases, today announced the completion of full enrollment in the 4-week dose expansion cohort of its Phase 1b clinical trial...